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Abstract
DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in 
ovarian cancer (OC). In this study, we elucidated an epigenetic signature associated with platinum 
drug re-sensitization that may offer utility in predicting the outcomes of patients who are co-
administered a DNA methyltransferase inhibitor. The OC specimens we analyzed were derived 
from a recent clinical trial that compared the responses of patients with recurrent platinum-
resistant OC who received carboplatin plus the DNA methyltransferase inhibitor guadecitabine or 
a standard of care chemotherapy regimen selected by the treating physician. Tumor biopsies or 
malignant ascites were collected from patients before treatment (day 1, cycle 1) or after treatment 
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(after 2 cycles) for epigenomic and transcriptomic profiling using the Infinium 
HumanMethylation450 BeadChip (HM450). We defined 94 gene promoters that were 
hypomethylated significantly by guadecitabine, with 1659 genes differentially expressed in pre-
treatment vs. post-treatment tumors. Pathway analysis revealed that the experimental regimen 
significantly altered immune re-activation and DNA repair pathways. Progression-free survival 
correlated with baseline expression levels of 1155 genes involved in 25 networks. In functional 
investigations in OC cells, engineered upregulation of certain signature genes silenced by 
promoter methylation (DOK2, miR-193a and others) restored platinum drug sensitivity. Overall, 
our findings illuminate how inhibiting DNA methylation can sensitize OC cells to platinum drugs, 
in large part by altering gene expression patterns related to DNA repair and immune activation, 
with implications for improving the personalized care and survival outcomes of OC patients.
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Introduction
Advanced stage ovarian cancer (OC) has poor outcome, five-year survival rates remaining 
less than 25% despite advances in therapy(1,2). Although most women with OC initially 
respond to platinum-based chemotherapy, relapses occur in most patients, leading to the 
development of platinum-resistance, which is uniformly fatal(3,4). It has been postulated 
that OC progression to a platinum resistant state is intimately linked to accumulated 
epigenomic alterations, including increased DNA methylation and modifications of histone 
marks(5–7). Such changes cause transcriptional repression of tumor suppressor (TSGs) and 
of other genes associated with apoptotic responses to chemotherapy(8,9). For example, 
promoter methylation has been involved in silencing of TSGs (e.g. BRCA1, MLH1, 
RASSF1A, DAPK, DOK2, OPCML) and of differentiation-associated transcription factors 
like HOXA10 and HOXA11(5,10,11) and was linked to OC initiation and chemotherapy 
resistance(8,9).
Based on this rationale, over the past decade, others and we have conducted bench-to-clinic 
therapeutic interventions targeting aberrant DNA methylation to re-sensitize ovarian tumors 
to platinum (12–18). In phase I clinical trials, combinations of platinum and 
hypomethylating agents were found to be tolerable and biologically active, as measured 
through global and gene-specific DNA methylation assays in peripheral blood mononuclear 
cells (PBMCs) and tumors. Two subsequent phase 1/2 clinical trials demonstrated significant 
clinical efficacy of combination regimens using DNA methyltransferase inhibitors 
(DNMTIs, decitabine or 5-azacitadine) and platinum, including long progression-free 
survival (PFS) and high response rates (RR) in platinum resistant OC(15,19). These 
observations supported a randomized clinical trial testing a next generation DNMT inhibitor 
guadecitabine (formerly known as SGI-110, Astex Pharmaceuticals, Inc.), and carboplatin 
against physician’s choice chemotherapy (NCT01696032), which was recently 
completed(20). Guadecitabine administered daily for 5 days had been found to be tolerable, 
biologically and clinically active in a previous trial in patients with myelodysplasyic 
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syndrome and acute myelogenous leukemia(21). Tumor biopsies or cancer cells harvested 
from malignant ascites were collected at baseline and after 2 cycles of treatment. Methylome 
and transcriptome analyses determined guadecitabine-induced changes in paired tumor 
biopsies and correlations with PFS. The randomized study was preceded and supported by a 
phase I component which demonstrated tolerability of guadecitabine at a dose of 30 mg/m2 
daily for 5 days preceding carboplatin administration on day 8 in OC patients(18). 
Pharmacodynamic analyses conducted using PBMCs showed that the regimen was 
biologically active, as evidenced by ~20% decrease in global LIRE1 (LINE1) DNA 
methylation(18). Together with the observed clinical activity, these data provided strong 
rationale for pursuing the randomized phase II trial. Clinical results of the study will be 
reported separately.
Here, we show that guadecitabine delivered daily over 5 days in low dose alters the 
epigenome and transcriptome of ovarian tumors, particularly impacting the expression of 
pathways associated with immune reactivation and DNA repair. Expression of 293 genes on 
day 1 cycle 1 organized in networks related to immune response processes were associated 
with PFS, supporting the hypothesis that clinical endpoints are impacted by the biological 
activity of the DNMTI. Further, we identified several TSGs (e.g. DOK2, miR193a) whose 
regulation was directly linked to the development of platinum resistance in OC cell lines. 
However, we believe that alteration of functional pathways, rather than of specific 
transcripts, are responsible for the clinical activity induced by the combination regimen. A 
key pathway impacted by treatment with the DNMTI and associated with longer PFS relates 
to T cell-mediated immune response, suggesting that alterations in the tumor 
microenvironment induced by guadecitabine contribute to the clinical effects of this new 
resensitization regimen.
Materials and Methods
Patients
Patients with platinum-resistant recurrent high-grade serous, endometrioid, mixed cell or 
clear cell epithelial OC (Grade 2 or 3); primary peritoneal carcinomatosis (PPC); or 
fallopian tube (FT) cancer were eligible for treatment. Eligible patients had acceptable organ 
function based on laboratory data, Eastern Cooperative Oncology Group performance status 
(ECOG PS) of 0 or 1, were at least 3 weeks from the last therapy. The protocol and informed 
consent form were reviewed and approved by an Institutional Review Board/Independent 
Ethics Committee at each study center prior to implementation. Patients provided written 
informed consent before enrollment. The study is registered on ClinicalTrials.gov, number 
NCT01696032 and was conducted in accordance with the International Council for 
Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, applicable local regulatory 
requirements, and the principles enunciated in the Declaration of Helsinki.
Study Design
This study had 2 stages: A safety lead-in stage (Stage 1) followed by a randomized, 
controlled, open-label stage (Stage 2). Study design is detailed in Supplemental Material 
(SM). Tumor biopsies or malignant ascites/or pleural fluid were obtained from consenting 
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patients at baseline (Cycle 1, Day 1) and after 2 cycles of guadecitabine + carboplatin (G+C) 
(Cycle 2, Day 8, prior to the carboplatin infusion) by imaging-guided core biopsies. Two 18-
gauge cores were obtained for each time point and material was immediately snap frozen 
(~25–50mg/specimen). Ascites or pleural fluid was centrifuged and fluid and cell pellets 
were separated prior to cryo-preservation.
Cell lines and culture
The ovarian cancer cell lines OVCAR3 and SKOV3 were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA), and the OVCAR5 cell line from the 
Developmental Therapeutics Program at the National Cancer Institute. Cell culture 
conditions and transfection are described in SM. The SKOV3 and OVCAR3 cell lines were 
authenticated by the ATCC in 2012 and 2015, respectively. The OVCAR 5 cell line was 
authenticated by IDEXX BioResearch (Columbia, MO) in 2015.
DNA and RNA extraction
DNA and total RNA were extracted from ~25 mg tumor tissue or 200 µL ascitic fluid using 
AllPrep DNA/RNA/Protein Mini kit (Qiagen, Valencia CA) following the manufacturer’s 
protocol. RNA used for real-time RT-PCR was extracted from cultured cells with TRI-
Reagent (Sigma-Aldrich) or a miRNeasy kit (Qiagen). DNA and RNA concentrations were 
determined using the absorbance at 260 nm, and purity was assessed based on the 260/280 
nm absorbance ratio.
Methylome analysis
DNA extracted from patient samples was bisulfite converted and DNA methylation was 
assayed by using the Infinium Human Methylation 450 BeadChip (HM450; Illumina) at the 
University of Chicago Genomics Facility. Data preprocessing and analyses were conducted 
in the statistical programming environment R v3.1.2 with the package RnBeads v0.99 
(16,22,23). Normalization and background correction were applied to methylation data with 
manufacture recommended algorithms implemented in methylumi package (see SM 
(24,25)). Methylation levels were averaged for the replicates for each biopsy after 
normalization and the difference in methylation β-value between two groups or the mean of 
the pairwise difference for paired samples was calculated. To correct p-values for multiple 
hypothesis testing, false discovery rates (FDR) was calculated by using an improved 
Benjamini-Hochberg procedure(26), and the methylation changes in CpG sites/regions with 
FDR < 0.05 were considered statistically significant. Ingenuity Pathway Analysis (IPA) was 
used to identify functional interactions of genes differentially methylated between groups. 
Average methylation signals on the CpG sites within each CpG island and/or promoter 
region were hierarchically clustered with Pearson dissimilarity and average linkage as 
clustering parameters.
In the analysis of the genomic context distribution of CpG sites, individual sites were 
annotated in regards to positional context relative to nearby CpG island and transcriptional 
starting site (TSS) based on the Illumina HumanMethylation450 BeadChip manifest. CpG 
islands were defined as DNA regions longer than 500 bases containing more than 55% GC 
content and with an observed-to-expected CpG ratio greater than 40%. CpG shores were 
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defined as 2Kb regions immediately upstream and downstream of CpG islands and CpG 
shelves were defined as 2–4Kb regions from the islands. CpGs unrelated to a CpG islands 
were classified as “open sea”. CpG sites were considered as being linked to a transcript if 
they mapped to the 200 to 1500 bases region upstream of TSS (TSS1500), within 200 bases 
upstream (TSS200), 5’UTR, 1st exon, gene body or 3’UTR. All other CpG sites not mapping 
to the above-mentioned regions relative to a transcript were defined as ‘not linked to gene’. 
The Illumina HumanMethylation450 BeadChip results are available for download at Gene 
Expression Omnibus (GEO) data repository at the National Center for Biotechnology 
Information (NCBI) under the accession number GSE102119.
Transcriptome analysis
RNA-sequencing was performed essentially as we have described (27,28). See SM for 
detailed description. The resulting reads were mapped against GRCh38.p5 using TopHat2 
version 2.1.1(29). TopHat uses Bowtie, which is based on the Burrows-Wheeler transform 
algorithm, for sequence alignment and allows for mapping across exon junctions(25). Read 
counts for each gene were created using HTSeq-Count from the HTSeq package version 
0.6.1p1 and Gencode v23 as the annotation(30,31). Custom perl scripts were used for 
estimation of transcript abundances based on fragments per kilobase of exon per million 
fragments mapped (FPKM). The differential expression analysis was carried out using the 
DESeq2 package (version 1.12.3) in R/Bioconductor (R version 3.3.1)(32). DESeq2 fits a 
generalized linear model (GLM) of the negative binomial family, and a Wald test is 
performed to evaluate the significance of the coefficients. To define broad pathway 
responses, gene expression changes in the paired biopsies were assessed using KEGG, GO 
and pathway analysis IPA and GeneGo. The RNA-sequencing results are available for 
download at Gene Expression Omnibus (GEO) data repository at the National Center for 
Biotechnology Information (NCBI) under the accession number GSE102118.
Real-time RT-PCR
For validation of the RNA-sequencing data, qRT-PCR for selected targets was done as we 
have described (see SM) (16).
Cell proliferation
Cell survival was measured using a Cell Counting Kit-8 (Dojindo Molecular Technologies, 
Inc., Rockville, MD) according to the protocol provided by the manufacturer. Absorbance at 
450 nm was determined with an EL800 microplate reader (BioTek Instruments, Inc., 
Winooski, VT). Student’s t-tests were used to compare experimental groups. P<0.05 was 
considered significant.
Clonogenic Assay
Cells were seeded on 6-well plates at the density of 100 cells per well and cultured for 10 
days. Colonies were fixed with 4% paraformaldehyde, stained with 1% crystal violet in 2% 
ethanol, and then counted. Student’s t-tests were used to compare experimental groups. 
P<0.05 was considered significant.
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Correlation of C1D1 levels with clinical outcome
Correlations of C1D1 promoter methylation and gene expression profiles with clinical 
outcomes were conducted using both logistic and Cox regression. For the logistic regression 
models, the outcome was PFS ≤ 91 days (the median time to PFS) vs PFS > 91 days. For 
Cox regression models, the outcome was PFS. Promoter methylation and gene expression 
levels were tested separately with the false discovery rate (FDR) controlled at the 0.05 level. 
For the DNA methylation data, M values were adapted to correlate with clinical outcomes. 
Potential covariates considered included age, race (white, black, Asian, other), ECOG score 
(0 or 1), ovarian cancer (yes/no), fallopian tube cancer (yes/no), crossover from TC (yes/no), 
and number of treatment regimens > 3 (yes/no). A step-wise selection method was used to 
determine final covariate models, and p value < 0.05 was used as the threshold for inclusion 
of a covariate. Covariates in the final models included ECOG, crossover from treatment 
choice (TC), race and number of treatment regimens > 3. Models were fit using R v3.1.2 
(glm and coxph functions).
Results
Study population
Figure 1A illustrates the study design. 124 subjects were enrolled in the study and 120 were 
treated (see SM). A total of 98 subjects received G+C (20 subjects in Stage 1, 51 subjects in 
Stage 2, and 27 TC subjects who were crossed over to G+C after disease progression in 
Stage 2). Figure 1B illustrates treatment administration schema and timing of tumor 
biopsies. “Baseline” biopsies were collected pre-guadecitabine on cycle 1 day 1 (C1D), and 
post-treatment were collected after two full cycles of daily × 5 doses of guadecitabine on 
day 8 (C2D8). Pre-guadecitabine (C1D1) tumor biopsies were obtained from 42 patients 
enrolled on this trial, of which 40 yielded high quality nucleic acids, while post-
guadecitabine (C2D8) biopsies were obtained from 11 patients, of which 9 yielded high 
quality nucleic acids. Malignant fluid collection on C1D1 and C2D8 were obtained from 23 
and 8 patients, respectively (Fig. 1C). Clinical and DNA methylation data at C1D1 were 
available for 35 patients. Clinical and RNA-sequencing data at C1D1 were available for 33 
patients.
Genome-wide effects of guadecitabine on DNA methylation
Epigenetic deregulation contributes to both the onset and maintenance of chemoresistance. 
To evaluate biological effects of the regimen G+C, demethylating activity in vivo was 
assessed. Global DNA methylation was assessed by using the Infinium 
HumanMethylation450 BeadChip (HM450) arrays on tumor biopsies collected at baseline 
on C1D1 (n = 40) and post-treatment collected on C2D8 (n = 9). Differential methylation 
was conducted in both CpG site level and region level. P value after multiple comparison 
correction FDR 0.05 was considered as significant, 18644 sites and 191 promoters were 
found significantly differentially methylated in tumor samples after treatment. Results of the 
differential methylation between treatment and baseline in paired tumor and paired ascites 
are shown as volcano plots in Fig. 2. Methylation changes were defined based on the β-value 
for each CpG site with a Δβ>0.2 for patients within a group for gene hypermethylation and 
Δβ<0.2 for hypomethylation (i.e., “demethylation”). Setting a significance threshold of P< 
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0.01 and displaying CpG site differential methylation (post- vs. pre- treatment) as volcano 
plots, we describe 94 genes with significantly altered CpGI methylation levels between 
paired tumor biopsies (pre- vs. post-treatment; Fig. 2A, left panel indicated by the shift to 
the left, red dots are differentially methylated CpG sites with FDR<0.05), and 17 genes had 
significantly altered CpGI methylation levels between paired ascites (Fig. 2A, right panel).
Since the lists of differentially methylated genes (Supplementary Table S1) in tumors (94 
genes) and ascites (17 genes) by themselves do not provide immediate insights into the 
biological mechanisms of response to the combined therapy, we examined the pathways 
enriched by genes hypomethylated after guadecitabine treatment by using IPA. Significantly 
enriched pathways in the paired tumor biopsies were related to altered metabolism and 
signaling (Fig. 2B, left), while the most enriched pathways in the ascites were related to 
DNA damage and repair and epithelial-to-mesenchymal transition (EMT) (Fig. 2B, right). 
One of the pathways enriched by guadecitabine-induced hypomethylation in tumors was 
14-3-3σ, a pathway involved in DNA repair and chemoresistance (33). To define 
biologically meaningful molecular interactions, we constructed gene-gene interaction 
networks for the two top networks, Immuno-Response-Related and DNA Replication and 
Repair for tumors (Fig. 2C, left) and ascites (Fig. 2C, right). These results demonstrate 
significant guadecitabine-induced gene demethylation in tumors and ascites, affecting 
interacting gene pathways and networks that potentially contribute to platinum resistance 
and can be involved in reversal of resistance by the hypomethylating agent.
The probes interrogated on the HumanMethylation450 array are distributed between CpG 
islands (~one third), regions flanking the CGIs (within 4Kb of the nearest island) referred to 
as “shelves” and “shores” and representing another third of all sites, and sites unrelated to an 
island, generally occurring within the gene body and termed as “open sea” sites, which 
represent another third of all probes. The differentially methylated sites were primarily 
found in the open sea (46%), vs. islands (18%), shores (17%) and shelves (18%) (Fig. 2D, 
left). Of all guadecitabine hypomethylated sites, 9% were within 1500 bp of the TSS or in 
the first exon of a gene, while another 8% and 6% respectively were found in the 3’ UTR 
and 5’ UTR respectively (Fig. 2D, right). A significant percentage of differentially 
methylated sites in response to guadecitabine resided in gene bodies (~65%).
Guadecitabine-induced transcriptomic changes
To examine global gene expression changes induced by guadecitabine in tumors, we 
performed RNA-sequencing on tumor samples (C1D1/baseline, 39 patients; vs. C2D8/post-
treatment, 8 patients). First, the tumor content of the biopsies was ascertained by using a 
Nonnegative Matrix Factorization (NMF) approach (see SM). All specimens, except one 
(which was subsequently excluded from analyses), had tumor content ≥60%, exceeding the 
tumor purity of the TCGA OC samples (See Supplementary Fig 1). 502 genes were 
significantly up-regulated by guadecitabine (fold change>2, FDR<0.05) (Supplementary 
Table S2). The heatmap in Figure 3A and Supplementary Table S2 illustrates significant 
transcriptomic changes induced by guadecitabine treatment (C2D8-orange samples) 
compared to pre-treatment (C1D1, green). Up- and down-regulated genes are marked by red 
and blue, respectively. To further investigate the potential functional relevance of the 
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differentially expressed genes before (C1D1) and after (C2D8) guadecitabine, IPA was 
performed. The most significant pathways altered in response to treatment were 
interleukin-8 (IL8, −log(p-val)=8.31; Fig. 3B) followed by signaling by Rho Family 
GTPases (−log(p-val)=7.55; Fig. 3B). Of the top 45 pathways, the most highly enriched 
were predominantly immune-related (15/45) and cancer signaling (20/45) pathways (Fig. 
3B, Fig. S2). Also noteworthy was enrichment of the DNA double-strand break repair by 
homologous recombination pathway (−log(p-val)=2.05; Fig. S2), an important pathway 
involved in chemo-resistance and -resensitization. The complete list of enriched pathways is 
included in Supplementary Figure S2. Networks were also constructed by IPA among the 
top 1659 differentially expressed genes (FC> 2, FDR<0.05). The top networks predicted to 
be activated by guadecitabine were immune response (phagocytes, neutrophils, leukocytes), 
adhesion of immune cells and homing of leukocytes (Fig. 3C, center hubs; red and green 
circles represent up- or down-regulated genes activating (or inhibiting) these immune 
networks shown on periphery), suggesting that the hypomethylating agent upregulated the 
immune signaling/response in vivo.
Integrated methylome-transcriptome analysis
DNA methylation plays an important role in gene regulation and by inducing demethylation, 
DNMTIs can cause gene upregulation. To examine the relationships between CpG island 
methylation and gene expression in tumor cells after treatment with guadecitabine, we 
performed an integrated transcriptome-methylome analysis on all C1D1 v. C2D8 tumor 
samples. As CpG island hypermethylation has been shown to directly silence genes, we 
focused on promoter CpG island-containing genes that were hypomethylated and 
upregulated after guadecitabine treatment and identified 77 genes meeting this criteria (Fig. 
4A and Supplementary Table S3) and observed separate clustering of the C1D1 (green) from 
C2D8 (orange) samples. The network constructed from the 77 reactivated genes included 
changes in T lymphocyte chemotaxis, inflammatory response, migration of neutrophils, 
adhesion of immune cells, and homing of leukocytes (Fig. 4B), in total predictive of a 
significantly altered immune response after guadecitabine treatment. Overall, our integrated 
‘omics analysis showed that guadecitabine induced a potent reprogramming of the ovarian 
cancer methylome and transcriptome to drive major immunomodulatory changes.
Relationship of guadecitabine-upregulated genes and clinical responses
At C1D1, 1155 genes were significantly associated with PFS in the multivariable Cox 
regression analysis after correcting for multiple comparisons (Fig. 5A; Supplementary Table 
S4). Pathways enriched by the 1155 genes include DNA damage-induced 14-3-3σ signaling 
(Fig. 5B; also seen enriched in Fig. 2B). After guadecitabine treatment, of the 1155 genes, 
203 were significantly demethylated (p<0.05, Supplemental Table S5) (Fig. 5C). Among this 
group of demethylated/reexpressed genes with C1D1 levels that correlated with clinical 
outcomes, cancer metabolic pathways and the transcriptional regulatory network of 
embryonic stem cells were enriched (Fig. 5C). An additional 293 genes upregulated by 
guadecitabine (FC>1.3, p<0.05, Supplemental Table S6) had C1D1 levels that correlated 
with clinical outcome. Pathways enriched in the group of PFS-associated genes included 
molecular mechanisms of cancer, apoptosis signaling, cancer metabolism (e.g., amino acid 
degradation and biosynthesis), and netrin signaling, a tumor suppressor pathway known to 
Fang et al. Page 8
Cancer Res. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
be inactivated by methylation in other cancer types (Fig. 5D). No significant correlations 
were found between promoter methylation or gene expression and PFS by logistic 
regressions or between C1D1 methylation and PFS by Cox regressions after correcting for 
multiple comparisons.
Functional validation
We used in vitro cellular assays to validate and further investigate specific genes and 
pathways of interest, selected based on the RNA-sequencing and DNA methylation analyses, 
our previous studies, and other reports describing their positive contributions to DNA 
damage-associated apoptosis and/or OC prognosis/outcome. For validation, we selected two 
genes re-expressed in response to guadecitabine representing functional classes, TSGs and 
cellular signaling (docking protein 2, DOK2 and miR193a) (Fig. 6A). Both DOK2, an 
adapter protein downstream of tyrosine kinase, and miR-193a, have been previously 
reported to play tumor suppressive roles in cancer and to modulate chemo-resistance(34–
36).
Treatment of OC cell lines SKOV3, OVCAR3 and OVCAR5 with the DNMT inhibitor 
decitabine significantly increased the expression of both DOK2 and miR193a (Fig. 6B and 
6C). To determine the mechanism by which gene reactivation by guadecitabine resensitizes 
OC cells to platinum therapy, we overexpressed DOK2 (Fig. 6D) or miR-193a (Fig. 6E) in 
OC cells and examined functional changes using cell proliferation and clonogenic assays in 
vitro. DOK2 overexpression significantly lowered the concentration of cisplatin required to 
inhibit SKOV3 OC cell proliferation compared to control (Fig. 6F). Furthermore, miR-193a 
overexpression decreased (P<0.05) proliferation (Fig. 6E) and colony formation of SKOV3 
(Fig. 6G) OC cells, supporting a tumor suppressor function. These results demonstrate that 
DNA methylation inhibitors lead to upregulation of expression of genes silenced in OC, 
induce cancer cell growth inhibition, improve chemosensitivity, likely contributing to the 
clinical benefit recorded in the trial.
Furthermore, we validated one of the pathways found to be enriched in hypomethylated 
genes in guadecitabine-treated tumors (Fig. 2B), which is involved in cell cycle control and 
response to chemotherapy (SFN also known as 14-3-3-σ). Knock down of 14-3-3σ by 
shRNA (Fig. 7A) resulted in increased sensitivity to cisplatin (Fig. 7B), decreased colony 
formation ability (Fig. 7C) and cell proliferation (Fig. 7D). These results support the 
involvement of 14-3-3σ in platinum resensitization and tumor growth inhibition induced by 
the regimen.
Discussion
Here we present integrated methylomic and transcriptomic analyses of tumor specimens 
obtained at baseline and after 2 cycles of guadecitabine and carboplatin from women with 
recurrent, platinum resistant OC enrolled in a randomized phase 2 trial comparing this 
strategy against physician’s choice of standard chemotherapy. These tumor analyses 
revealed profound gene expression changes induced by the hypomethylating agent in 
combination with platinum. Furthermore C1D1 values of these same genes were correlated 
with observed clinical effects of the regimen. Our study has several important implications.
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First, the clinical trial from which tumor and ascites specimens were collected and analyzed 
represents the first randomized comparison between a novel epigenome targeting strategy 
and the standard chemotherapy approach for platinum resistant OC. The concept of 
methylome targeting used in our trial is rooted in accumulating evidence that chromatin 
changes associated with DNA methylation occur during cancer progression as a 
consequence of cellular stress, chronic inflammation, and DNA damage. DNMT inhibitors 
have been shown to be global chromatin remodelers and to exert untargeted effects on the 
epigenome. While these agents have shown clear activity in myelodysplasia and leukemia, 
where they are approved for clinical use, their development in solid tumors has lagged due to 
difficulties of designing tolerable combinations with chemotherapy (37) or biological 
therapy, and limitations in clinical trial design. In recent years, our group and others have 
shown that DNMT inhibitors can be safely combined with platinum when using low 
repetitive doses, which maintain drug biological activity (12,15,19). The clinical results of 
the current study are reported separately, but of note is that the median rate of PFS at 6 
months was 37% for the experimental regimen compared to 13% for physician’s choice 
treatment (P=0.05), suggesting that the methylome-targeted regimen induces platinum re-
sensitization in this setting, and is clinical active.
Second, we show here that guadecitabine induced significant hypomethylation in tumor 
biopsies and in cells recovered from ascites fluid. These observations are consistent with 
analyses of PBMCs from patients enrolled in this trial in which guadecitabine-induced 
demethylation of LINE1 elements was recorded (18). Differences between networks of 
genes hypomethylated in tumors vs. ascites likely reflect differences in tumor milieu and the 
“metastatic” state of tumor cells in ascites, with EMT being one of the prominent pathways 
affected. Significant guadecitabine-induced hypomethylation was also noted in vivo by our 
group in preclinical studies using OC xenografts treated with this agent (13,16). Global 
hypomethylation promoted by other DNMTIs in clinical specimens was demonstrated in 
previous studies testing either decitabine or 5-azacitadine in patients with OC or solid 
tumors (12,15,38). Our study is limited by lack of histological confirmation, due to scant 
material obtained through core biopsies and prioritization of nucleic acid extraction for 
genomic analyses. To mitigate this limitation, an NMF strategy deconvoluted the 
transcriptomic data and samples included in analyses had a predicted tumor content 
exceeding 60% (see SM, Supplementary Table 7). CIBERSORT analysis confirmed that the 
observed significantly demethylated/methylated CpG sites were independent of infiltrating 
lymphocytes in pre-/post- treatment tissues (See SM, Supplementary Table 8 and 
Supplementary Figure 3). Additionally, changes in post-treatment tumor biopsies may 
reflect not only effects of HMA, but also cellular stress in response to platinum.
Interestingly, more than half of guadecitabine-induced differentially methylated sites 
occurred in gene bodies, consistent with prior observations, which identified such sites as 
becoming demethylated in response to DNMTIs and rapidly rebounding after the inhibition 
was removed(39). While the significance of gene body site methylation is not fully 
elucidated, emerging evidence points to such sites located near enhancer regions as potential 
regulators of gene expression (40). Additionally, removal of gene body CG sites methylation 
has been shown to be associated with increased H2A.Z occupancy and enrichment in 
H3K27me3, contributing to regulation of gene transcription (39).
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Integration of methylomic and transcriptomic signals induced by DNMTIs has been 
generally difficult to demonstrate in human specimens. This is partly explained by variable 
clinical responses in small data sets and limitations of using core biopsies, which generate 
small amounts of high quality nucleic acids. Additionally, we acknowledge the nonspecific 
activity of hypomethylating agents, which exert genome wide effects. It is likely that the re-
sensitization effects induced by the regimen are not caused by a single transcript re-
expression, but by genome wide reprogramming and activation (or inhibition) of cancer-
relevant pathways. Interestingly, among the hypomethylated and re-expressed pathways in 
tumors, we identified gene networks related to DNA repair, metabolism, and immune 
response, similar to our previous findings in the phase I/II clinical trial using decitabine in 
combination with carboplatin(15). A number of metabolic pathways were represented 
among genes found to be hypomethylated and associated with clinical outcomes. These 
results are consistent with findings in colon cancer cells exposed to 5-azacitadine, where 
gene body hypomethylation affected primarily metabolic processes regulated by c-
MYC(39).
An important observation from our study relates to reactivation of immune response 
pathways in ovarian tumors treated with guadecitabine. These results are consistent with our 
previous and others’ recent findings that epigenome reprogrammers elicit immune 
stimulation in vivo (15,41,42). A proposed mechanism is DNMTI-induced tumor antigen 
reexpression (43), as previously shown for the cancer-testis antigen NY-ESO-1 and MAGE 
antigens, which are frequently repressed epigenetically in ovarian tumors (43,44) and re-
expressed as a consequence of treatment with hypomethylating agents (45,46). A recent 
study using preclinical OC models showed that T helper responses are repressed 
epigenetically and that removal of this break using epigenetic modulators potentiates 
response to immunotherapy, including checkpoint inhibitors (47). Additionally, two other 
studies reported that DNMTIs induce immune signaling in cancer cells by augmenting the 
viral response pathway and inducing re-expression of endogenous retroviral genes 
incorporated in the human genome (48,49), suggesting that other immunogenic pathways are 
also regulated epigenetically. These observations suggest that epigenetic modulators, in 
particular DNMTIs and HDAC inhibitors may serve as potent primers for immune directed 
therapy. Indeed, in a phase I study, decitabine potentiated the effects of a NY-ESO-1 directed 
vaccine, augmenting T-cell immune responses and inducing anti-tumor activity (46) and 
several new clinical trials exploring combinations of immunotherapy and DNMT inhibitors 
have recently been activated.
Lastly, we demonstrate that guadecitabine and carboplatin promote reactivation of a number 
of genes and pathways with tumor suppressor function. Among genes re-expressed in tumor 
specimens after guadecitabine, we validated that DOK2 and miR193a are silenced 
epigenetically in ovarian cancer cell lines. Upon re-expression in response to guadecitabine, 
DOK2 re-sensitized OC cells to platinum and inhibited cancer cell proliferation and 
clonogenicity, consistent with its previously described functions(50). Likewise, we show that 
miR193a has tumor suppressor function and is rapidly induced by hypomethylating agents. 
Lastly, forced downregulation of 14-3-3σ, a pathway whose activation in response to 
guadecitabine associated with clinical outcomes, inhibited cancer cell proliferation and 
clonogencity and resensitized OC cells to platinum.
Fang et al. Page 11
Cancer Res. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In conclusion, coupled with the clinical results of this study, our tissue-based analyses 
provide important insight into the mechanisms by which methylome-targeting strategies 
exert anti-tumor effects. We show that global DNA hypomethylation induced by 
guadecitabine affects metabolic and immune responses and reactivates TSGs, which 
contribute to response to platinum. Our data suggest that guadecitabine resensitizes ovarian 
tumors to platinum, however anti-tumor effects exerted by the novel DNMTI either directly, 
or indirectly via immune reactivation, cannot be excluded and support future studies 
exploring hypomethylating agents with other biological interventions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study population
A) Study design includes phase 1 (cohorts I and II) and randomized phase 2. AUC: area 
under the curve; G+C: guadecitabine + carboplatin; TC: treatment choice. B) Treatment 
administration schema and timing of tumor biopsies. C) Summary of sample collection.
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Figure 2. Methylome changes induced by guadecitabine
A) Volcano plots of CpG site methylation analysis. Plots of log P value versus log2 fold 
change for paired (C1D1 vs. C2D8) biopsies (tumors, left; ascites, right). See Supplemental 
Table S1 for full list of significantly demethylated genes. B) Pathways enriched by 
significantly demethylated genes induced by guadecitabine (adjusted P value<0.05) in paired 
biopsies (tumors, left; ascites, right). C) Two top networks constructed by Immune-
Response-Related and DNA Replication and Repair induced by guadecitabine in paired 
biopsies (tumors, left; ascites, right). D) Pie charts showing the distribution of genomic 
context of the differentially methylated CpG sites examined (left and right charts show 
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genomic context relative to a nearby CpG island or a gene, which defined by Illumina 
manifest).
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Figure 3. Transcriptomic changes induced by guadecitabine
A) Heatmap shows significant transcriptomic changes induced by guadecitabine. Patient IDs 
are listed on top of the heatmap, and C1D1 (baseline) is coded in green, while C2D8 (post-
treatment) is coded in orange (genes shown here are adjusted P<0.05, |fold change|>2). B) 
Selected immuno-related pathways enriched by differentially expressed genes (adjusted P 
value<0.05, |fold change|>2) (full pathways lists are in Supplementary Figure 2 A and B). C) 
Networks of immune response constructed using significantly changed genes by 
guadecitabine.
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Figure 4. Integrated methylome-transcriptome analysis
A) A heatmap shows 77 integrated genes that were hypomethylated at promoter CpG island 
and upregulated (mRNA expression) after guadecitabine treatment. C1D1 (baseline) is 
coded in green, while C2D8 (post-treatment) is coded in orange. Gene list is shown in 
Supplementary Table S3. B) Immune-related networks constructed by the 77 integrated 
genes.
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Figure 5. Associations between guadecitabine-upregulated genes and clinical outcomes
A) A heatmap shows significant up-regulated genes (associated with PFS) by guadecitabine. 
Adjusted p value<0.05, fold change>1.3. B) Pathways enriched by 1155 genes whose 
expression profiles significantly associated with PFS in multivariate Cox regression. C) 
Pathways enriched by hypomethylated CpG sites in genes associated with PFS. D) Pathways 
enriched by up-regulated genes that are associated with PFS. Adjusted p value<0.05, fold 
change>1.3.
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Figure 6. Docking protein 2 (DOK2) and microRNA 193a (MIR193A) genes are responsive to 
DNA demethylation and inhibit proliferation in OC cells
A) Changes in expression of 25 selected genes measured by RNAseq in OC tumors before 
(n=40) and after (n=9) guadecitabine treatment. The MIR193A and DOK2 genes, which 
were selected for further validation analyses, are highlighted. B) DOK2 mRNA expression 
levels measured by real-time RT-PCR in SKOV3, OVCAR3, and OVCAR5 OC cells treated 
with the hypomethylating agent decitabine (DAC) for 72 hours. C) Real-time RT-PCR 
measurements of MIR193A mRNA expression levels in SKOV3, OVCAR3, and OVCAR5 
OC cells treated with DAC for 72 hours. D) DOK2 mRNA expression levels measured by 
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real-time RT-PCR in SKOV3 cells stably transduced with a vector containing the DOK2 
gene. E) Proliferation measured by the CCK8 assay of SKOV3 cells overexpressing or not 
(Control) the MIR193A gene. F) Survival (CCK8 assay) of SKOV3 cells stably transduced 
to overexpress the DOK2 gene and treated with cisplatin for 48 hours. G) Clonogenicity of 
SKOV3 cells overexpressing the MIR193A gene. In B, C, D, E, F and G, experiments were 
repeated three times, bars represent mean ± SD, n=3. *, P<0.05.
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Figure 7. Inhibition of stratifin (SFN gene) in OC cells diminishes cell proliferation and increases 
sensitivity to platinum
A) Expression levels of the stratifin (SFN) gene in SKOV3 cells stably transfected with 
control shRNA or shRNA targeting the SFN gene (shSFN, n=3, P<0.05). B) Survival 
measured by the CCK8 assay of SKOV3 cells transfected with control shRNA or shSFN and 
treated with cisplatin at the doses indicated (n=3, *P<0.05). C) Clonogenicity of SKOV3 
cells transfected with control shRNA or shRNA targeting the SFN gene (shSFN, n=3, 
*P<0.05). D) Proliferation of SKOV3 cells transfected with control shRNA or shRNA 
targeting the SFN gene (shSFN, n=3, *P<0.05).
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